Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cyclacel Pharmaceuti (NQ: CYCC ) 1.270 -0.050 (-3.79%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Cyclacel Pharmaceuti < Previous 1 2 3 4 5 6 Next > Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session June 20, 2023 Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740. Via Benzinga Why Cano Health Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket June 20, 2023 Gainers Via Benzinga Recap: Cyclacel Pharmaceuticals Q1 Earnings May 11, 2023 Via Benzinga Oppenheimer Maintains Outperform Rating for Cyclacel Pharmaceuticals: Here's What You Need To Know March 07, 2023 Via Benzinga A Preview Of Cyclacel Pharmaceuticals's Earnings March 03, 2023 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday June 20, 2023 It's time for another dive into the biggest pre-market stock movers as we check out all the latest news for Tuesday morning! Via InvestorPlace Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update May 11, 2023 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results May 04, 2023 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit May 03, 2023 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals to Participate in March Investor Conferences March 07, 2023 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update March 06, 2023 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results February 27, 2023 From Cyclacel Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's After-Market Session February 16, 2023 Via Benzinga Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference January 30, 2023 From Cyclacel Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Pre-Market Session January 17, 2023 Via Benzinga Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023 January 05, 2023 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023 December 15, 2022 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update November 09, 2022 From Cyclacel Via GlobeNewswire Earnings Outlook For Cyclacel Pharmaceuticals November 08, 2022 Cyclacel Pharmaceuticals (NASDAQ:CYCC) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that... Via Benzinga Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results November 03, 2022 From Cyclacel Via GlobeNewswire Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022 October 26, 2022 Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patients From Cyclacel Via GlobeNewswire Cyclacel Hosting Research & Development Day October 24, 2022 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium October 13, 2022 - Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma - From Cyclacel Via GlobeNewswire Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday August 17, 2022 We've got the news behind the biggest pre-market stock movers for Wednesday morning that traders need to know about this morning! Via InvestorPlace This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday August 19, 2022 Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday. Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session August 11, 2022 Via Benzinga Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session August 18, 2022 Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66. Via Benzinga Why Is Disney Higher By More Than 7%: Here Are 40 Stocks Moving Premarket August 11, 2022 Gainers Via Benzinga Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday August 12, 2022 Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results. Via Benzinga Why Matterport Is Trading Higher By Around 25%, Here Are 73 Stocks Moving In Thursday's Mid-Day Session August 11, 2022 Gainers Timber Pharmaceuticals, Inc. (NYSE: TMBR) shares rose 63.8% to $0.1769. Timber Pharmaceuticals recently announced closing of $8.0 million public offering. Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.